patients treated "long" course with chloroquine or hydroxychloroquine, in particular for autoimmune diseases, have not been less affected by severe forms of Covid-19 during the epidemic, shows a French study published on Tuesday.

This study, conducted on nearly 55,000 patients, " does not suggest a preventive role of the use of antimalarials, synthesis (APS) - long course on the risk of occurrence of a hospitalization, intubation, or death related to the Covid-19 ", conclude the authors.